Immunotherapy combo shows promise for chinese cancer patients

NCT ID NCT03195478

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now complete, and results will help determine if this combination is a viable option for this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to: If it works, this could offer a new treatment option for Chinese patients with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply to everyone. The combination can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Local Institution

Guangzhou, Guangdong, 510080, China
Local Institution

Zhengzhou, Henan, 450052, China
Local Institution - 0001

Beijing, Beijing Municipality, 100142, China
Local Institution - 0004

Tianjin, Tianjin Municipality, 300222, China
Local Institution - 0011

Harbin, Heilongjiang, 155040, China
Local Institution - 0012

Guangzhou, Guangdong, 510655, China
Local Institution - 0013

Hangzhou, Zhejiang, 310009, China
Local Institution - 0015

Beijing, Beijing Municipality, 100021, China
Local Institution - 0016

Shanghai, Shanghai Municipality, 200025, China
Local Institution - 0018

Chengdu, Sichuan, 610041, China
Local Institution - 0020

Xi'an, Shan1xi, 710061, China
Local Institution - 0021

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.